Physicians' experiences with BRCA1/2 testing in community settings

Journal of Clinical Oncology

Volumn 26, Issue 35, 2008, Pages 5789-5796

  Keating, Nancy L ^a   Stoeckert, Kathryn A ^a   Regan, Meredith M ^a   DiGianni, Lisa ^a   Garber, Judy E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; EXPERIENCE; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETICS; GYNECOLOGY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MEDICAL PRACTICE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUTATION; ONCOLOGY; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RISK MANAGEMENT; UNITED STATES;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COMMUNITY HEALTH SERVICES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PATIENT CARE TEAM; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; UNITED STATES;

EID: 57449112328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.8053     Document Type: Article

References (34)

1. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
2. Weitzel JN: Genetic cancer risk assessment. Putting it all together. Cancer 86:2483-2492, 1999 (suppl)
3. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2 - Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
4. Hoskins KF, Stopfer JE, Calzone KA, et al: Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. JAMA 273:577-585, 1995
5. Daly M: NCCN practice guidelines: Genetics/familial high-risk cancer screening. Oncology (Huntingt) 13:161-183, 1999
6. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
7. Wideroff L, Freedman AN, Olson L, et al: Physician use of genetic testing for cancer susceptibility: Results of a national survey. Cancer Epidemiol Biomarkers Prev 12:295-303, 2003
8. American College of Medical Genetics: Policy Statement: Genetic Susceptibility to Breast and Ovarian Cancer - Assessment, Counseling and Testing Guidelines. http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm
9. National Comprehensive Cancer Network: Genetic/familial high-risk assessment: Breast and ovarian, V. 1.2007. http://wwwnccnorg/professionals/ physician_gls/PDF/genetics_screeningpdf 2007
10. Bernhardt BA, Geller G, Doksum T, Metz SA: Evaluation of nurses and genetic counselors as providers of education about breast cancer susceptibility testing. Oncol Nurs Forum 27:33-39, 2000
11. Freedman AN, Wideroff L, Olson L, et al: US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 120A:63-71, 2003
12. Armstrong K, Weber B, FitzGerald G, et al: Life insurance and breast cancer risk assessment: Adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A 120A:359-364, 2003
13. Peterson EA, Milliron KJ, Lewis KE, et al: Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11:79-87, 2002
14. Chen WY, Garber JE, Higham S, et al: BRCA1/2 genetic testing in the community setting. J Clin Oncol 20:4485-4492, 2002
15. Peshkin BN, Demarco TA, Graves KD, et al: Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: Rationale and development of a randomized controlled trial. Genetic Testing 12:37-52, 2008
16. National Comprehensive Cancer Network: Practice guidelines in oncology-breast cancer, v. 1.2005. http://wwwnccnorg/professionals/ physician_gls/PDF/breastpdf 2005
17. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
18. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004
19. Guillem JG, Wood WC, Moley JF, et al: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642-4660, 2006
20. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999
21. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001
22. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
23. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004
24. van Sprundel TC, Schmidt MK, Rookus MA, et al: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93:287-292, 2005
25. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
26. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
27. Armstrong K, Schwartz JS, Randall T, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 22:1045-1054, 2004
28. Nattinger AB, Gottlieb MS, Veum J, et al: Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 326:1102-1107, 1992
29. Peshkin BN, Isaacs C, Finch C, et al: Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: A pilot survey of physicians. J Clin Oncol 21:4322-4328, 2003
30. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881, 2000
31. Gronwald J, Tung N, Foulkes WD, et al: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118:2281-2284, 2006
32. Osin PP, Lakhani SR: The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Breast Cancer Res 1:36-40, 1999
33. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002
34. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006